Toronto Dominion Bank raised its stake in Laboratory Corp. of America Holdings (NYSE:LH) by 0.8% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 66,269 shares of the medical research company’s stock after buying an additional 544 shares during the quarter. Toronto Dominion Bank owned 0.07% of Laboratory Corp. of America worth $11,506,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in the business. Schwab Charles Investment Management Inc. boosted its holdings in shares of Laboratory Corp. of America by 0.8% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 389,086 shares of the medical research company’s stock worth $69,853,000 after buying an additional 3,039 shares during the period. Homrich & Berg bought a new stake in shares of Laboratory Corp. of America during the 2nd quarter worth $245,000. Polaris Greystone Financial Group LLC bought a new stake in shares of Laboratory Corp. of America during the 3rd quarter worth $3,967,000. Lee Financial Group Hawaii Inc. boosted its holdings in shares of Laboratory Corp. of America by 3.5% during the 3rd quarter. Lee Financial Group Hawaii Inc. now owns 16,653 shares of the medical research company’s stock worth $2,892,000 after buying an additional 565 shares during the period. Finally, Private Advisor Group LLC bought a new stake in shares of Laboratory Corp. of America during the 2nd quarter worth $656,000. Hedge funds and other institutional investors own 92.10% of the company’s stock.

A number of analysts have weighed in on LH shares. Craig Hallum reduced their price target on shares of Laboratory Corp. of America from $201.00 to $193.00 and set a “buy” rating for the company in a report on Wednesday, October 3rd. Morgan Stanley increased their price target on shares of Laboratory Corp. of America from $192.00 to $202.00 and gave the company a “buy” rating in a report on Monday, September 10th. Argus reissued a “buy” rating on shares of Laboratory Corp. of America in a report on Wednesday, August 22nd. Canaccord Genuity reissued a “buy” rating and issued a $200.00 price target on shares of Laboratory Corp. of America in a report on Tuesday, July 24th. Finally, Bank of America started coverage on shares of Laboratory Corp. of America in a report on Friday, October 19th. They issued a “buy” rating for the company. Eight analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $192.19.

NYSE:LH opened at $161.00 on Wednesday. The stock has a market cap of $16.32 billion, a PE ratio of 16.77, a price-to-earnings-growth ratio of 1.52 and a beta of 1.00. Laboratory Corp. of America Holdings has a 52 week low of $149.39 and a 52 week high of $190.35. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 0.83.

Laboratory Corp. of America (NYSE:LH) last released its quarterly earnings data on Wednesday, October 24th. The medical research company reported $2.74 EPS for the quarter, missing analysts’ consensus estimates of $2.88 by ($0.14). The business had revenue of $2.83 billion for the quarter, compared to the consensus estimate of $2.84 billion. Laboratory Corp. of America had a return on equity of 17.13% and a net margin of 13.27%. Laboratory Corp. of America’s revenue was up 8.0% on a year-over-year basis. During the same period in the previous year, the business posted $2.46 earnings per share. On average, equities research analysts expect that Laboratory Corp. of America Holdings will post 11.33 EPS for the current year.

In related news, Director Kerrii B. Anderson sold 3,700 shares of the stock in a transaction dated Monday, November 5th. The shares were sold at an average price of $163.29, for a total transaction of $604,173.00. Following the completion of the sale, the director now owns 21,795 shares in the company, valued at approximately $3,558,905.55. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.73% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION NOTICE: This news story was first posted by Daily Political and is owned by of Daily Political. If you are accessing this news story on another website, it was stolen and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this news story can be read at https://www.dailypolitical.com/2018/11/21/toronto-dominion-bank-grows-holdings-in-laboratory-corp-of-america-holdings-lh.html.

Laboratory Corp. of America Profile

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates through two segments, LabCorp Diagnostics and Covance Drug Development. It offers a range of clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C, prostate-specific antigen, tests for sexually-transmitted diseases, hepatitis C tests, vitamin D, microbiology cultures and procedures, and alcohol and other substance-abuse tests that are used by hospitals, physicians and other healthcare providers and commercial clients to assist in the diagnosis, monitoring and treatment of diseases and medical conditions through the examination of substances in blood, tissues, and other specimens.

Further Reading: Capital gains and your 401(k) or IRA

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Laboratory Corp. of America Holdings (NYSE:LH).

Institutional Ownership by Quarter for Laboratory Corp. of America (NYSE:LH)

Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.